Abcellera Biologics Inc Cash Flow Conversion Efficiency
Abcellera Biologics Inc cash flow conversion efficiency. Based on the latest financial reports, Abcellera Biologics Inc (ABCL) has a cash flow conversion efficiency ratio of -0.038x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-33.86 Million) by net assets ($896.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Abcellera Biologics Inc (2018–2025)
Cash flow conversion efficiency of Abcellera Biologics Inc from 2018 to 2025. This chart illustrates how Abcellera Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ABCL share price today for real-time trading data and today's change.
Abcellera Biologics Inc Cash Flow Conversion Ratio Explained
Abcellera Biologics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Abcellera Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abcellera Biologics Inc ranked by their cash flow conversion efficiency. Also see Abcellera Biologics Inc (ABCL) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First Capital Real Estate Investment Trust
TO:FCR-UN
|
0.008x |
|
Westgold Resources Ltd
AU:WGX
|
0.177x |
|
Enaex S.A
SN:ENAEX
|
0.099x |
|
Kinetik Holdings Inc
NYSE:KNTK
|
0.063x |
|
Taichung Commercial Bank Co Ltd
TW:2812
|
-0.105x |
|
GEK TERNA Holdings Real Estate Construction S.A
AT:GEKTERNA
|
0.030x |
|
Treasury Wine Estates Ltd
AU:TWE
|
0.030x |
|
HARBOUR ENE.SP.ADR LS-50
F:PQQ2
|
N/A |
Annual Cash Flow Conversion Efficiency for Abcellera Biologics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Abcellera Biologics Inc from 2018 to 2025. Review ABCL free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $966.90 Million | $-131.29 Million | -0.136x | -32.10% |
| 2024-12-31 | $1.06 Billion | $-108.56 Million | -0.103x | -169.95% |
| 2023-12-31 | $1.15 Billion | $-43.88 Million | -0.038x | -116.93% |
| 2022-12-31 | $1.23 Billion | $277.36 Million | 0.225x | -5.68% |
| 2021-12-31 | $1.03 Billion | $244.58 Million | 0.238x | +772.78% |
| 2020-12-31 | $830.51 Million | $22.69 Million | 0.027x | -89.60% |
| 2019-12-31 | $10.25 Million | $2.69 Million | 0.263x | -14.43% |
| 2018-12-31 | $11.61 Million | $3.56 Million | 0.307x | -- |
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more